Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.918 |
High Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.9106 |
High Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.888 |
High Similarity |
NPD3027 |
Phase 3 |
0.8819 |
High Similarity |
NPD1613 |
Approved |
0.8819 |
High Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.84 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.84 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.839 |
Intermediate Similarity |
NPD228 |
Approved |
0.832 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.8244 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.8211 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.814 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.811 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.8095 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.8 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7939 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7929 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7862 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7829 |
Intermediate Similarity |
NPD4749 |
Approved |
0.782 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7817 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7812 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7808 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7805 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7744 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7708 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7703 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7623 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7623 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7603 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7603 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7568 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7559 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7552 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7521 |
Intermediate Similarity |
NPD968 |
Approved |
0.7518 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.75 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7479 |
Intermediate Similarity |
NPD291 |
Approved |
0.7467 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7459 |
Intermediate Similarity |
NPD290 |
Approved |
0.745 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7442 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7429 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7426 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7426 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7414 |
Intermediate Similarity |
NPD9296 |
Approved |
0.7405 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7405 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7398 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7368 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7355 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7355 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7355 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7333 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7333 |
Intermediate Similarity |
NPD9494 |
Approved |
0.7319 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7319 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7319 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7302 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7292 |
Intermediate Similarity |
NPD2219 |
Phase 1 |
0.7292 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7285 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7266 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7266 |
Intermediate Similarity |
NPD6671 |
Approved |
0.726 |
Intermediate Similarity |
NPD4123 |
Phase 3 |
0.7226 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7218 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7215 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7211 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.719 |
Intermediate Similarity |
NPD940 |
Approved |
0.719 |
Intermediate Similarity |
NPD846 |
Approved |
0.7183 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7183 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7181 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7181 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.7174 |
Intermediate Similarity |
NPD3145 |
Approved |
0.7174 |
Intermediate Similarity |
NPD3144 |
Approved |
0.7171 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.717 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.717 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7161 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7153 |
Intermediate Similarity |
NPD3060 |
Approved |
0.7153 |
Intermediate Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.7152 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7152 |
Intermediate Similarity |
NPD37 |
Approved |
0.7143 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7133 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7133 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7133 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7132 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7132 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7124 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7124 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7124 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7123 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7122 |
Intermediate Similarity |
NPD2674 |
Phase 3 |
0.7103 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7083 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7083 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7075 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7071 |
Intermediate Similarity |
NPD943 |
Approved |
0.7071 |
Intermediate Similarity |
NPD1240 |
Approved |
0.707 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7063 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7063 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7044 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7043 |
Intermediate Similarity |
NPD9094 |
Approved |
0.7042 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7042 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7042 |
Intermediate Similarity |
NPD6111 |
Discontinued |
0.7042 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7037 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7034 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7034 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7034 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7034 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7034 |
Intermediate Similarity |
NPD4162 |
Approved |
0.7034 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7031 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7027 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7027 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7023 |
Intermediate Similarity |
NPD1408 |
Clinical (unspecified phase) |
0.7019 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7015 |
Intermediate Similarity |
NPD1535 |
Discovery |
0.7014 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7008 |
Intermediate Similarity |
NPD9280 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.6993 |
Remote Similarity |
NPD1510 |
Phase 2 |
0.6992 |
Remote Similarity |
NPD17 |
Approved |
0.6992 |
Remote Similarity |
NPD6516 |
Phase 2 |
0.6992 |
Remote Similarity |
NPD5846 |
Approved |
0.6986 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6985 |
Remote Similarity |
NPD8651 |
Approved |
0.6985 |
Remote Similarity |
NPD3225 |
Approved |
0.698 |
Remote Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.6975 |
Remote Similarity |
NPD7251 |
Discontinued |
0.6975 |
Remote Similarity |
NPD2934 |
Approved |
0.6975 |
Remote Similarity |
NPD2933 |
Approved |
0.6972 |
Remote Similarity |
NPD1607 |
Approved |
0.697 |
Remote Similarity |
NPD1182 |
Approved |
0.6963 |
Remote Similarity |
NPD9269 |
Phase 2 |
0.6963 |
Remote Similarity |
NPD1481 |
Phase 2 |
0.6959 |
Remote Similarity |
NPD7213 |
Phase 3 |
0.6959 |
Remote Similarity |
NPD6799 |
Approved |
0.6959 |
Remote Similarity |
NPD7212 |
Phase 2 |
0.6951 |
Remote Similarity |
NPD8054 |
Approved |
0.6951 |
Remote Similarity |
NPD8053 |
Approved |
0.6939 |
Remote Similarity |
NPD6190 |
Approved |
0.6933 |
Remote Similarity |
NPD7808 |
Phase 3 |
0.6933 |
Remote Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.6933 |
Remote Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.6929 |
Remote Similarity |
NPD556 |
Approved |
0.6917 |
Remote Similarity |
NPD2859 |
Approved |
0.6917 |
Remote Similarity |
NPD2860 |
Approved |
0.6914 |
Remote Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.6912 |
Remote Similarity |
NPD6583 |
Phase 3 |
0.6912 |
Remote Similarity |
NPD6582 |
Phase 2 |
0.6906 |
Remote Similarity |
NPD1008 |
Clinical (unspecified phase) |
0.6905 |
Remote Similarity |
NPD1358 |
Approved |
0.6901 |
Remote Similarity |
NPD4340 |
Discontinued |
0.6899 |
Remote Similarity |
NPD6232 |
Discontinued |
0.6899 |
Remote Similarity |
NPD821 |
Approved |
0.6894 |
Remote Similarity |
NPD5844 |
Phase 1 |
0.6885 |
Remote Similarity |
NPD3020 |
Approved |
0.6879 |
Remote Similarity |
NPD6233 |
Phase 2 |
0.6875 |
Remote Similarity |
NPD5960 |
Phase 3 |
0.6875 |
Remote Similarity |
NPD5588 |
Approved |
0.6871 |
Remote Similarity |
NPD3892 |
Phase 2 |
0.6871 |
Remote Similarity |
NPD6331 |
Phase 2 |
0.6871 |
Remote Similarity |
NPD4628 |
Phase 3 |
0.6871 |
Remote Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.6871 |
Remote Similarity |
NPD4110 |
Phase 3 |
0.6866 |
Remote Similarity |
NPD1778 |
Approved |
0.6864 |
Remote Similarity |
NPD9365 |
Approved |
0.6861 |
Remote Similarity |
NPD2922 |
Phase 1 |
0.6861 |
Remote Similarity |
NPD6696 |
Suspended |
0.6859 |
Remote Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.6859 |
Remote Similarity |
NPD7075 |
Discontinued |
0.6846 |
Remote Similarity |
NPD5297 |
Approved |
0.6842 |
Remote Similarity |
NPD7534 |
Approved |
0.6842 |
Remote Similarity |
NPD7533 |
Approved |
0.6824 |
Remote Similarity |
NPD2677 |
Approved |
0.6812 |
Remote Similarity |
NPD1203 |
Approved |
0.6809 |
Remote Similarity |
NPD5109 |
Approved |
0.6809 |
Remote Similarity |
NPD5110 |
Phase 2 |
0.6809 |
Remote Similarity |
NPD6798 |
Discontinued |
0.6809 |
Remote Similarity |
NPD5111 |
Phase 2 |
0.68 |
Remote Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.6797 |
Remote Similarity |
NPD4380 |
Phase 2 |
0.6786 |
Remote Similarity |
NPD3537 |
Clinical (unspecified phase) |
0.6783 |
Remote Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.6783 |
Remote Similarity |
NPD5124 |
Phase 1 |
0.6783 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6783 |
Remote Similarity |
NPD5735 |
Approved |
0.6783 |
Remote Similarity |
NPD111 |
Approved |
0.6781 |
Remote Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.6779 |
Remote Similarity |
NPD5058 |
Phase 3 |
0.6776 |
Remote Similarity |
NPD3686 |
Approved |
0.6776 |
Remote Similarity |
NPD3687 |
Approved |
0.6774
|
Remote Similarity |
NPD7096 |
Clinical (unspecified phase) |